By in

Directors’ appointments/resignation

Press Release                                                                                                                    16 August 2018

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

 (“Sativa” or the “Company”) 

Directors’ appointments/resignation

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has appointed Jonathan Peter Wearing as an independent non-executive director and Angus Jeremy Kerr as a non-executive director of the Company.

Noel Lyons, independent non-executive director of the Company, has resigned from the Company.

Geremy Thomas, founder and Chief Executive Officer of Sativa, said: “Sativa listed in March and since then there has been a seismic shift in UK Governmental attitude to medicinal cannabis, and therefore the anticipated UK opportunities are likely to materialise earlier. 

“Sativa led the way as the UK’s first medicinal cannabis investment vehicle, and strengthening its Board gives the Company additional depth to take advantage of the huge potential that the UK market may well offer.” 

Jonathan Peter Wearing(aged 65)

Jonathan joins as non-Executive Chairman.  Jonathan is an experienced, City-based corporate financier, who began his City career after graduating from Cambridge University with a M.A. in Economics.  He was Chairman of Ideagen plc on its admission to the AIM market in July 2012 until April 2018 and remains a non-Executive Director.  Following eight years in Citibank London’s corporate banking division, providing debt finance for growth and acquisition purposes, he moved to Citicorp’s London investment bank (CIBL) where, as a Director in the Corporate Finance Department, he worked on both UK and cross-border transactions. 

As at the date of this announcement, Jonathan has an interest in 50,000 ordinary shares in the Company. 

Angus Jeremy Kerr(aged 48)

Angus is an adviser and capital markets professional with nearly 25 years’ experience in global banking with specific expertise in strategic and equity advisory, M&A and ECM. He has held, inter alia, managing director and management roles covering advisory, equity advisory and ECM at a number of organisations, including head of Mid-Market Advisory and Broking at Credit Suisse and head of UK ECM Dresdner Kleinwort. He has a long track record of advising companies and high profile individuals in the UK, USA and Europe.

He is currently a Senior Advisor at Zeus Capital, the independent investment bank, and is also Chairman of North Berwick SA, a business that consolidates portfolios of company-owned life insurance, and of the advisory board of Luxon Payments Ltd, a company using block chain distributed ledger technology to create a global electronic wallet.

Prior to his career in finance Angus was an Army Officer. Angus has a BA (Hons) in Politics and International Relations from the University of Reading.

As at the date of this announcement, Mr Kerr does not have an interest in any ordinary shares of the Company.

Jonathan Wearing

Jonathan has been a director or partner of the following companies/partnerships in the last five years:

Current Directorships and Partnerships

Past Directorships and Partnerships

CAMBRIDGE POLYMER TECHNOLOGIES LTD

IDEAGEN CAPTURE LIMITED

CITY UNIT RESIDENTS MANAGEMENT LTD

EMROS PARTNERS LIMITED

CONTINUATION POLYGELCO HOLDINGS

 

GARLIC PLANT PRODUCTS LTD

 

HURSTMOUNT LTD

 

J. P. WEARING & CO LTD

 

IDEAGEN PLC

 

POLYGELCO LTD

 

TRICASTLE INVESTMENTS LTD

 

Pursuant to Paragraph 21, Appendix 1 of the NEX Exchange Growth Market – Rules for Issuers, Jonathan Wearing has previously been a director of the following companies:

(a)  Geoffrey Parker’s Country Workshop Limited (“GPCW”) until it was dissolved on 8 August 1997. GPCW was put into creditors voluntary liquidation on 16 May 1995. According to the statement of affairs there was an estimated deficiency to creditors of approximately £105,294. GPCW was dissolved on 8 August 1997 following the final meeting of the creditors dated 2 May 1997 that the company be wound up under the provisions of the Insolvency Act 1986; and

(b)  Garlic Farms (UK) Limited (“Garlic Farms”) until it was dissolved on 22 April 2010. On 4 May 2006 an administration order was made in respect of Garlic Farms. The administration order was discharged on 16 May 2007 when Garlic Farms went into creditors voluntary liquidation. According to the statement of affairs on 4 June 2007 there was an estimated deficiency to creditors of approximately £258,816. Garlic Farms was dissolved on 22 April 2010 following the final meeting of the creditors dated 12 January 2010 that the company be wound up under the provisions of the Insolvency Act 1986.

Angus Kerr

Angus has been a director or partner of the following companies/partnerships in the last five years:

Current Directorships and Partnerships

Past Directorships and Partnerships

Elixir Strategy Limited

African Value Capital Investments

North Berwick S.A.

 

There is no further information that is required to be disclosed pursuant to Paragraph 21, Appendix 1 of the NEX Exchange Growth Market – Rules for Issuers.

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

 

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private.  Sativa Investments has made a range of investments including Canadian-based and dual-listed emerging global pharmaceutical company,Veritas Pharma Inc., Toronto-based Pharma-Tech company that owns the patent-pending proprietary QuickStrip™ technology, Rapid Dose Therapeutics Inc., and UK-based CBD products provider George Botanicals. 

 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation and the required testing of products such as CBD oil through its own testing laboratory, PhytoVista Laboratories. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.com/